Morgan Stanley
PHVS icon

Morgan Stanley’s Pharvaris PHVS Stock Holding History

Morgan Stanley’s Portfolio PHVS Stock Details PHVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.64M Sell
164,323
-84,011
-34% -$2.24M ﹤0.01% 4193
2025
Q4 		$6.89M Buy
248,334
+190,071
+326% +$4.58M ﹤0.01% 3935
2025
Q3 		$1.45M Sell
58,263
-1,509
-3% -$33.5K ﹤0.01% 4962
2025
Q2 		$1.05M Sell
59,772
-15,593
-21% -$251K ﹤0.01% 5066
2025
Q1 		$1.18M Buy
75,365
+48,368
+179% +$816K ﹤0.01% 4929
2024
Q4 		$518K Buy
26,997
+2,746
+11% +$56.5K ﹤0.01% 5402
2024
Q3 		$449K Buy
24,251
+955
+4% +$17.5K ﹤0.01% 5454
2024
Q2 		$438K Sell
23,296
-5,745
-20% -$117K ﹤0.01% 5350
2024
Q1 		$671K Sell
29,041
-15,935
-35% -$423K ﹤0.01% 5177
2023
Q4 		$1.26M Buy
44,976
+11,279
+33% +$228K ﹤0.01% 5193
2023
Q3 		$703K Sell
33,697
-11,635
-26% -$214K ﹤0.01% 4994
2023
Q2 		$686K Sell
45,332
-3,653
-7% -$35.3K ﹤0.01% 5051
2023
Q1 		$395K Buy
48,985
+10,805
+28% +$95.1K ﹤0.01% 5394
2022
Q4 		$430K Buy
38,180
+19,085
+100% +$100K ﹤0.01% 5319
2022
Q3 		$146K Buy
19,095
+2,279
+14% +$35.6K ﹤0.01% 5891
2022
Q2 		$372K Buy
16,816
+631
+4% +$11.8K ﹤0.01% 5570
2022
Q1 		$294K Sell
16,185
-2,071
-11% -$36.5K ﹤0.01% 5707
2021
Q4 		$262K Buy
18,256
+709
+4% +$11.1K ﹤0.01% 5917
2021
Q3 		$311K Sell
17,547
-2,437
-12% -$41.7K ﹤0.01% 5761
2021
Q2 		$372K Buy
19,984
+15,149
+313% +$344K ﹤0.01% 5702
2021
Q1 		$135K Buy
+4,835
New +$152K ﹤0.01% 5866

Other funds holding PHVS

GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
EFM
EQT Fund Management Luxembourg $1.02B AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Morgan Stanley's PHVS Position: Q1 2026 in Review

Morgan Stanley reduced its Pharvaris (PHVS) stake by 34% in Q1 2026, selling an estimated $2.24M and leaving 164,323 shares worth $4.64M. The position accounts for ﹤0.01% of the portfolio, ranked #4193.

Morgan Stanley first reported a position in PHVS in Q1 2021 and has held it in 21 quarters since. The position peaked at $6.89M in Q4 2025. 110 funds tracked by Wall St. Rank hold PHVS as of Q1 2026.

  • Morgan Stanley held 164,323 shares of Pharvaris worth $4.64M as of Q1 2026.
  • Morgan Stanley sold 84,011 Pharvaris shares in Q1 2026, an estimated $2.24M.
  • Pharvaris made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #4193 holding.
  • Morgan Stanley first reported a position in Pharvaris in Q1 2021 and has held it in 21 quarters since.
  • Morgan Stanley's Pharvaris position peaked at $6.89M in Q4 2025.
  • 110 funds tracked by Wall St. Rank held Pharvaris as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.